

### Claims

1. An antibody specific for CD38 comprising a heavy chain complementarity determining region (HCDR) 1 comprising an amino acid sequence of SEQ ID NO: 12 or SEQ ID NO: 1, an HCDR2 comprising an amino acid sequence of SEQ ID NO: 2, an HCDR3 comprising an amino acid sequence of SEQ ID NO: 3, a light chain complementarity determining region (LCDR) 1 comprising an amino acid sequence of SEQ ID NO: 4, an LCDR2 comprising an amino acid sequence of SEQ ID NO: 5, and an LCDR3 comprising an amino acid sequence of SEQ ID NO: 6 for use in the treatment of a subject with autoantibody-mediated membranous nephropathy, wherein the antibody is formulated for administration at a fixed dose level.
2. An antibody specific for CD38 comprising an HCDR1 comprising an amino acid sequence of SEQ ID NO: 12 or SEQ ID NO: 1, an HCDR2 comprising an amino acid sequence of SEQ ID NO: 2, an HCDR3 comprising an amino acid sequence of SEQ ID NO: 3, an LCDR1 comprising an amino acid sequence of SEQ ID NO: 4, an LCDR2 comprising an amino acid sequence of SEQ ID NO: 5, and an LCDR3 comprising an amino acid sequence of SEQ ID NO: 6 for use in the preparation of a medicament for the treatment of a subject with autoantibody-mediated membranous nephropathy, wherein the antibody is formulated for administration at a fixed dose level.
3. The antibody for use according to claim 1 or 2, wherein the autoantibody-mediated membranous nephropathy is an anti-PLA2R-positive membranous nephropathy.
4. The antibody for use according to any one of the preceding claims, wherein the antibody is formulated for administration at a fixed dose corresponding to a body weight range of the subject.
5. The antibody for use according to claim 4, wherein the antibody is formulated for administration at a fixed dose of 650 mg, 975 mg, 1300 mg or 1625 mg, corresponding to a body weight range of < 50 kg, 50.5 to 70 kg, 70.5 to 90 kg, > 90.5 kg, respectively.

6. The antibody for use according to any one of claims 1-3, wherein the antibody is formulated for administration at a fixed dose of 16 mg/kg.
7. The antibody for use according to any of the preceding claims, wherein the antibody is formulated for administration in the initial 3 weeks once weekly (QW).
8. The antibody for use according to any of the preceding claims, wherein the antibody is formulated for administration once every two weeks (q2w).
9. The antibody for use according to any of the preceding claims, wherein the antibody is formulated for administration at the interval of i) day 1, day 8, day 15, day 29, and day 57 representing a 3 month treatment period or ii) day 1 and day 15 representing a 1 month treatment period.
10. The antibody for use according to claim 9, further comprising re-treatment 3 or 5 months after end of the preceding treatment period.
11. The antibody for use according to any one of claims 1-6, wherein the antibody is formulated for administration at the interval of day 1, day 8, day 15, and day 22, followed by day 29, day 57, day 85, day 113, and day 141 in a treatment period of 24 weeks.
12. The antibody for use according to any one of claims 1-6, wherein the antibody is formulated for administration at two doses in a treatment interval of 85 days.
13. The antibody for use according to any one of claims 1-6, wherein the antibody is formulated for administration at five doses in a treatment interval of 85 days.
14. The antibody for use according to any one of claims 1-6, wherein the antibody is formulated for administration at nine doses in a treatment interval of 24 weeks.

15. The antibody for use according to any one of claims 1-6, wherein the antibody is formulated for administration at nine doses in a treatment interval of 141 days.

16. The antibody for use according to any of the preceding claims, wherein the antibody is formulated for administration intravenously, optionally over a period of two hours.

17. The antibody for use according to any of the preceding claims, wherein the subject has a serum level of anti-PLA2R antibodies of  $\geq 50$  RU/mL,  $\geq 100$  RU/mL,  $\geq 150$  RU/mL,  $\geq 200$  RU/mL,  $\geq 250$  RU/mL,  $\geq 300$  RU/mL at screening.

18. The antibody for use according to claim 17, wherein the subject has a serum level of anti-PLA2R antibodies of  $\geq 150$  RU/mL.

19. The antibody for use according to any of the preceding claims, wherein the subject has a urine protein:creatinine ratio (UCPR; g/g) of  $\geq 3.0$  g/g,  $\geq 4.0$  g/g,  $\geq 5.0$  g/g,  $\geq 6.0$  g/g, or  $\geq 7.0$  g/g.

20. The antibody for use according to any of the preceding claims, wherein the subject has a proteinuria of  $\geq 3.5$  g/24 h,  $\geq 4.0$  g/24 h,  $\geq 4.5$  g/24 h or  $\geq 5.0$  g/24 h from a 24-hour urine screening.

21. The antibody for use according to any of the preceding claims, wherein the antibody leads to a change from baseline anti-PLA2R titer of  $>10\%$ ,  $>15\%$ ,  $>20\%$ ,  $>25\%$ ,  $>30\%$ ,  $>35\%$ ,  $>40\%$ ,  $>45\%$ ,  $>50\%$ ,  $>55\%$ ,  $>60\%$ ,  $>65\%$ ,  $>70\%$ ,  $>75\%$ ,  $>80\%$ ,  $>85\%$ ,  $>90\%$ ,  $>95\%$ , or  $100\%$  in the subject.

22. The antibody for use according to claim 21, wherein the subject has serum level of anti-PLA2R antibodies of  $\geq 50$  RU/mL, and a reduction of anti-PLA2R autoantibody titer compared to baseline of  $>10\%$ ,  $>15\%$ ,  $>20\%$ ,  $>25\%$ ,  $>30\%$ ,  $>35\%$ ,  $>40\%$ ,  $>45\%$ ,  $>50\%$ ,  $>55\%$ ,  $>60\%$ ,  $>65\%$ ,  $>70\%$ ,  $>75\%$ ,  $>80\%$ ,  $>85\%$ ,  $>90\%$ ,  $>95\%$ , or  $100\%$  at day 8 of cycle 1.

23. The antibody for use according to claim 5, wherein the antibody leads to a change from baseline anti-PLA2R titer of >10%, >15%, >20% >25%, > 30%, >35%, >40%, >45%, >50%, >55%, >60%, >65%, >70%, >75%, >80%, >85%, >90%, >95%, or 100% in the subject at day 8 of cycle 1.
24. The antibody for use according to claim 5, wherein the antibody leads to a change from baseline anti-PLA2R titer between 25% and 80% in the subject.
25. The antibody for use according to claim 24, wherein the antibody leads to a change from baseline anti-PLA2R titer between 25% and 80% over 4 weeks of treatment in the subject.
26. The antibody for use according to claim 5, wherein the antibody leads to a change from baseline anti-PLA2R titer of >80% in the subject.
27. The antibody for use according to claim 26, wherein the antibody leads to a change from baseline anti-PLA2R titer of >80% in the subject over 4 weeks of treatment.
28. The antibody for use according to claim 5, wherein the antibody does not increase the anti-PLA2R titer in the subject over 4 weeks of treatment.
29. The antibody for use according to any one of the preceding claims, wherein the antibody comprises a variable heavy chain (VH) comprising an amino acid sequence of SEQ ID NO: 7 and a variable light chain (VL) comprising an amino acid of sequence SEQ ID NO: 8.
30. The antibody for use according to any of the preceding claims, wherein the antibody comprises an IgG1 Fc region.
31. The antibody for use according to any of the preceding claims, wherein the antibody is formulated for administration in combination with 650 mg to 1,000 mg of oral paracetamol.

32. The antibody for use according to any of the preceding claims, wherein the antibody is formulated for administration in combination with 25 mg to 50 mg of oral or intravenous diphenhydramine.

33. The antibody for use according to any of the preceding claims, wherein the antibody is formulated for administration in combination with 100 mg of intravenous methylprednisolone, or an equivalent thereof.

34. The antibody for use of any of the preceding claims, wherein the antibody is felzartamab or a biosimilar thereof.